rozanolixizumab-noli recently approved by the fda under the name of RYTIGGO

rozanolixizumab-noli , a neonatal Fc receptor blocker indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive was recently approved by the fda under the name of RYTIGGO. (6.26.2023). Congrats to all the members of the researchanddevelopment team who contributed to this achievement! We at Magellan […]